Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectable products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India and China. Therefore, governments of such countries are focusing on reducing the cost of medications and increasing its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer products by 86% in March 2017.

Market Dynamics

Various India-based pharmaceutical companies are intended towards expansion of their distribution globally, leading to the generation of significant revenue which will aid in growth of generic oncology sterile injectables market in the region. For instance, in July 2017, Alembic Pharmaceuticals, an India-based company, inaugurated its manufacturing facility for generic oncology products in Gujarat that will cater to the markets in the Middle East, Africa, Asia, and North America. The manufacturing site has a capacity for 60 million tablets and capsules, and around 20 million vials capacity for liquid injectable and lyophilized products.

Similarly, in 2016, Sun Pharma expanded the company’s presence in Japan with the acquisition of 14 prescribed brands from Novartis for US$ 293 Mn.

Furthermore, Lupin, a pharmaceutical Indian firm active in Japan, announced in February 2016 that its subsidiary Kyowa is setting up a manufacturing plant in Tottori, to meet the rising demand for generics in Japan, where generics represent 49% of drug sales volume marking the second-largest drug market, after the U.S., in the world.

Key features of the study:

• This report provides an in-depth analysis of Asia Pacific generic oncology sterile injectable market, provides market size (US$ million), and compound annual growth rate (CAGR %) for the forecast period (2026-2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the Asia Pacific generic oncology sterile injectable market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Eli Lily and Company, Biocon Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd, Baxter International Inc., Hikma Pharmaceuticals, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The Asia Pacific generic oncology sterile injectable market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the Asia Pacific generic oncology sterile injectable market

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2021-2033)
  • Monoclonal Antibodies
  • Chemotherapy
    • Alkylating Agents
    • Antimetabolites
    • Plant Alkaloids
    • Antitumor Antibiotics
    • Others
  • Cytokines
  • Peptide Hormones
• By Disease Indication (Revenue, USD Bn, 2021-2033)
  • Ovarian Cancer
  • Breast Cancer
  • Lung Cancer
  • Pancreatic Cancer
  • Others
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Key Players
  • Eli Lily and Company
  • Biocon Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Reddy’s Laboratories Ltd
  • Baxter International Inc.
  • Hikma Pharmaceuticals
  • Mylan N.V.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.